BSD Medical Expands Distribution Network to Fully Cover Entire United States

Signs Distribution Agreement with KOL Bio-Medical Instruments, Inc.

SALT LAKE CITY--()--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, announced today that the company has signed an agreement with KOL Bio-Medical Instruments, Inc. (KOL) for the sales and distribution of BSD’s MicroThermX® Microwave Ablation (MicroThermX) line of products. KOL sales and distribution area will include up to 15 states in the Northeast, Mid-Atlantic and Southeast.

“This agreement with KOL fully expands our distribution network across the United States to include key states on the eastern seaboard, from Maine to Florida,” said Brian Ferrand, BSD Vice President of Domestic Sales. “KOL is a well-respected distributor that has solid and extensive relationships with interventional radiologists throughout the Eastern United States. Moreover, between our carefully selected mix of distributors and direct sales representatives, we now have full sales coverage throughout the entire United States. This should drive even greater recognition and adoption of our microwave ablation products in the marketplace and make us extremely accessible and responsive to our customers.”

Headquartered in Virginia, KOL is a Service Disabled Veteran Owned specialty distributor that has an extensive 40-plus year history of selling and distributing emerging medical technologies. For the past 40-years, KOL’s highly trained and experienced sales force has helped pioneer and introduce advanced medical devices to hospitals and clinicians throughout the Eastern United States.

About the MicroThermX® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator.

The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream.

The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.

Contacts

for BSD Medical Corporation
Tricia Ross, 310-622-8226
investor@bsdmc.com

Contacts

for BSD Medical Corporation
Tricia Ross, 310-622-8226
investor@bsdmc.com